bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 3816: Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways
Authors: Luan Baoxin , Zhao Hongbo , Bast Robert C. , Lu Zhen , Yu Yinhua 
Published: August 2019

Abstract
We have identified that Corilagin is a major anti-tumor active component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L. Our previous work found that Corilagin inhibited the growth of ovarian cancer cells via TGF-β/AKT/ERK signaling pathways. Corilagin also sensitizes Paclitaxel and Carboplatin by primarily inhibiting Snail-glycolysis pathways. Recently, we have investigated if Corilagin could give a help to overcome poly ADP ribose polymerase (PARP) inhibitors (PARPi) resistance in ovarian cancer cells. As we knew, PARP inhibitors are DNA repair drugs, have been approved for ovarian cancer therapy, but drug resistance is a faced problem, combination therapy may give helps. In this study, two pairs of PARPi sensitive/resistant cells: A2780CP/A2780CP_R and UMB1.289/UMB1.289_R (Sci Transl Med. 2017; 9:392) were used. Cells were cloned again and confirmed their sensitivities to PARPi. The IC50 of PARPi-BMN673 is 0.02μM to A2780CP, &gt 10μM to A2780CP_R, 0.12μM to UMB1.289 and 60μM to UMB1.289_R. The combination assays showed Corilagin had almost equally cytotoxic activities to these two pairs and had synergistic effects with BMN673 to A2780CP_R and UMB1.289_R . Using CulcuSyn, the combination indexes (CI) presented at IC50 are 0.17365 and 0.62787 in A2780_R and UMB1.289_R, respectively. Signaling analysis found that PARPi did down-regulate the expression levels of PARP and up-regulate of pH2AX, PARPi only inhibited pERK activity in sensitive cells, but not in resistant cells. In contrast, Corilagin did not have DNA repair function, but it inhibited pERK activity in both sensitive and resistant cells. In summary, we demonstrate that combined treatment with Corilagin and PARPi evokes synergistic cytotoxic effects in two pairs of ovarian cancer cell models. Corilagin is an herb medicine with lower toxic effects to normal cells, especially hepatoprotective, which could be an ideal complimentary medicine when combinating with PARPi in ovarian cancer therapy.
Citation Format: Baoxin Luan, Hongbo Zhao, Robert C. Bast, Jr., Zhen Lu, Yinhua Yu. Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3816.
Abstract 3823: Inhibition of homologous recombination, PARP inhibitor, or dianhydrodulcitol overcomes temozolomide-resistance in glioma cells
Authors: OHBA SHIGEO , Hirose Yuichi 
Published: August 2019

Abstract
Glioblastoma is one of the most aggressive tumors in the central nervous system tumors. The standard therapy for glioblastomas is maximal safe resection, followed by radiation therapy and chemotherapy with temozolomide (TMZ). The acquisition of resistance to TMZ is big problem. TMZ is a DNA-methylating agent, delivering a methyl group to DNA (O6-guanine, N7-guanine and N3-adenine). The primary cytotoxic lesion, O6-methylguanine, mispairs with thymine, leading to futile DNA mismatch repair (MMR), formation of double strand breaks and eventual cell death, when O6-methylguanine DNA methyltransferase (MGMT) is absent. N7-methylguanine and N3-methyladenine are repaired by base excision repair. The object of the study was to reveal the mechanisms of resistance to TMZ and to find the way to overcome the resistance in glioma cells. Several clones of TMZ-resistant U251 were obtained and analyzed. #3 clone showed G2 arrest after TMZ exposure and this arrest was abrogated sooner compared to parental U251. TMZ did not induce G2 arrest in #8 clone. The expression of MGMT was not found in U251 parental cells, #3 cells nor #8 cells. The ability of homologous recombination (HR) was increased in #3 clone, and suppression of HR resensitized #3 clone to TMZ. The protein levels of MSH6, which was one of the main proteins associated with MMR, was reduced in #8 clone. Inhibition of base excision repair by PARP inhibitor resensitized #8 clone to TMZ. Dianhydrodulcitol, alkylating agent, suppressed the proliferation in U251 and even U251-derived resistant clones. These effects were shown in U87MG-dereived resistant clones and MGMT-proficient cell lines. To select the way according to the mechanisms of resistance to TMZ could overcome the resistance in glioma cells.
Citation Format: SHIGEO OHBA, Yuichi Hirose. Inhibition of homologous recombination, PARP inhibitor, or dianhydrodulcitol overcomes temozolomide-resistance in glioma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3823.
Abstract 3856: MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib
Authors: Habib Nagy A. , Huang Kai-Wen , Reebye Vikash , Sodergren Mikael , Rossi John 
Published: August 2019

Abstract
MTLCEBPA, a non-toxic therapeutic oligonucleotide formulated inside SMARTICLES (liposomal nanoparticles) is currently under a Phase I study for patients with advanced hepatocellular carcinoma (HCC). We have demonstrated in multiple in vivo liver disease models that MTLCEBPA can improve liver function and inhibit HCC tumor growth. Here we show that upregulation of hepatic CEBPA expression by MTLCEBPA enhances the effects of Sorafenib in a (Diethylnitrosamine) DEN induced cirrhotic HCC rat model by significantly reducing liver tumor volume after only two weeks of combination treatment when compared to untreated control or single agent treatment only.
In this study, we established cirrhosis and HCC by exposing male Wistar rats to DEN for 6 weeks. Animals were randomized into 5 groups comprising of:
1. PBS control;
2. MTL-CEBPA treatment (TIW at 3mg/kg) for one week;
3. MTL-CEBPA treatment (TIW at 3mg/kg) for two weeks;
4. Sorafenib TIW at 10mg/kg for two weeks; and
5. MTLCEBPA at 3mg/kg at week one combined with Sorafenib 10mg/kg at week 2 group.
The results here indicate that Sorafenib combined with MTLCEBPA significantly inhibits tumor growth when compared to single agent treatment. Tumor sizes averaged at 644.7mm3 (± 88.57) in group 1 compared to 326mm3 (± 53.05) in group 2; 199.7mm3 (± 54.73) in group 3 and 299.5mm3 (± 77.1) in group 4. In combination treatment (group 5) the tumor
sizes averaged at 101.3mm3 (± 37.48). Serum AFP change (posttreatment values - pre-treatment) was more prominent in the MTLCEBPA/Sorafenib combination treatment (group 5) where there was a 4-fold reduction in values after treatment when compared to control groups 1-4. Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and total bilirubin remained unchanged across all the treatment groups suggesting no deterioration in liver function during the study period.
These results suggest that MTLCEBPA improved the efficacy of Sorafenib in this DEN induced HCC model, indicating a promising therapeutic option for advanced HCC patients who can no longer be treated with potentially more effective local therapies.
Citation Format: Nagy A. Habib, Kai-Wen Huang, Vikash Reebye, Mikael Sodergren, John Rossi. MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3856.
Abstract 3872: Targeting multi-functional ERK-protein complexes in vivo
Authors: Kaoud Tamer S. , Johnson William H. , Ebelt Nancy D. , Piserchio Andrea , Zamora-Olivares Diana , Ravenstein Sabrina V. , Pridgen Jacey R. , Edupuganti Ramakrishna , Sammons Rachel , Cano Micael , Warthaka Mangalika , Ren Pengyu , Anslyn Eric V. , Tsai Kenneth Y. , Ghose Ranajeet , Dalby Kevin N. 
Published: August 2019

Abstract
Mutations in pathways that enhance the activity of ERK1 and ERK2 are frequently present in human cancers, reflecting their important roles in tumor initiation, and progression. This notion is reinforced by observations in BRAF V600E mutant melanoma where the majority of the mechanisms of resistance to FDA-approved combination therapies targeting BRAF and MEK involve reactivation of ERK1 and ERK2. Recently, the direct targeting of the ERK enzymes using ATP-competitive inhibitors has emerged as an attractive strategy to overcome acquired resistance to current combination therapies. The ERK enzymes employ unique mechanisms of molecular recognition to engage protein components of the MAPK pathway. Here we report the potent targeting of an ERK-protein docking interaction by a small molecule thiotriazole, which abrogates ERK signaling in vivo. The thiotriazole binds covalently to a highly conserved cysteine residue within the D-recruitment site of ERK1/2 with more than a 100-fold discrimination over other MAPKs (e.g. JNK1/2, p38MAPKs and ERK5). Treatment of various BRAF-inhibitor naive or inhibitor-resistant melanoma cell lines expressing BRAF V600E with the thiotriazole for 2 hours induces dose-dependent inhibition of ERK activation and downstream signaling. Inhibition is maintained for up to 5 hours following thiotriazole washout and induces apoptosis and growth inhibition. Treatment of mice carrying a BRAFV600E A375 melanoma xenograft with the thiotriazole blocked tumor growth. Transient expression of a mutant form of ERK2, which is resistant to the thiotriazole, promotes survival of A375 and HEK 293 cells treated with thiotriazole. This study lays the foundation for developing a new modality for the treatment of solid tumors driven by excessive ERK signaling.
Citation Format: Tamer S. Kaoud, William H. Johnson, Nancy D. Ebelt, Andrea Piserchio, Diana Zamora-Olivares, Sabrina V. Ravenstein, Jacey R. Pridgen, Ramakrishna Edupuganti, Rachel Sammons, Micael Cano, Mangalika Warthaka, Pengyu Ren, Eric V. Anslyn, Kenneth Y. Tsai, Ranajeet Ghose, Kevin N. Dalby. Targeting multi-functional ERK-protein complexes in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3872.
Abstract 3876: Thymoquinone induces the expression of clock genes in breast cancer cells
Authors: Alamoudi Aliaa A. , Bashmail Hanan A. , Ajabnoor Ghada M. , Choudhry Hani , Hassan Mohammed A. , Aldahlawi Alia M. , Al-abd Ahmed A. 
Published: August 2019

Abstract
Thymoquinone is naturally occurring bioactive compound which showed cumulative preclinical evidence of anticancer effects. However, its exact anti-cancer activity remains to be elusive and is currently being studied. In this study, we assessed the role of thymoquinone as a potential therapy in human breast cancer cell lines in addition to its role in altering molecular clock genes expression, which in turn has been associated with tumorgenesis. Sulfa-Rhodamine-B assay (SRB) assay was used to evaluate the cytotoxic effect of thymoquinone in breast cancer cell lines (MCF-7 and T47D). Following 72 h of exposure, thymoquinone showed cytotoxic effects against MCF-7 and T47D with IC50’s of 44.4±3 µM and 152±11 µM respectively. Further investigation showed that thymoquinone showed some affect on the cell cycle distribution in both cell lines. It significantly increased the cell population in S-phase in MCF-7cells (P&lt;0.05), while causing a significant G1 phase arrest in T47D cells (p&lt;0.01). Interestingly, treatment of both cell lines with non-cytotoxic concentrations of thymoquinone resulted in a significant increased expression of clock genes, measured by reverse transcription–quantitative PCR (RT-qPCR). Thymoquinone appeared to increase the expression of BMAL-1 (1.4±0.1 fold), CLOCK (3.4±0.9 fold), PER-1(5.6±0.5 fold), CRY-1 (4.4±0.4 fold), CRY-2(2.2±0.6 fold) in MCF-7 cells. Similarly, thymoquinone increased the expression of BMAL-1 (1.4±0.3 fold), CLOCK (1.4±0.3 fold), PER-1(1.4±0.3 fold), CRY-1 (1.5±0.4 fold), and CRY-2 (1.8±0.1 fold) in T47D cells . In conclusion, thymoquinone possesses a potential in combating breast cancer alone. Despite the promising anti-proliferative activity of thymoquinone against breast cancer cells, the better understanding of these effects is needed to provide a novel approach for the treatment of breast cancer as a disease. Here, we postulate that the drug could be modulating clock genes expression, which ultimately can affect key molecules in cell cycle and cell proliferation. Further studies are needed to confirm this and to elucidate the exact underlying mechanism.
Citation Format: Aliaa A. Alamoudi, Hanan A. Bashmail, Ghada M. Ajabnoor, Hani Choudhry, Mohammed A. Hassan, Alia M. Aldahlawi, Ahmed A. Al-abd. Thymoquinone induces the expression of clock genes in breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3876.
Abstract 3878: Newly identified p53-pathway restoring small molecule, CB002 analog #4 induces apoptosis and appears non-toxic in vivo
Authors: Borrero Liz J. Hernandez , Lev Avital , Zhou Lanlan , Dicker David T. , El-Deiry Wafik S. 
Published: August 2019

Abstract
The transcription factor encoding TP53 tumor suppressor gene is mutated in more than half of human cancers. TP53 accounts for therapy resistance and poor patient survival in colorectal and other cancers. Upon cellular stress, p53 protein determines cell fate through the regulation of cell senescence, cell cycle arrest, and apoptosis pathways. Distinct from other tumor-suppressors, mutated p53 can acquire a gain-of-function activity, leading to chemotherapy resistance and a more aggressive tumor phenotype. Direct therapeutic targeting of transcription factors is challenging especially when reactivation is needed; thus, to date, there are no FDA approved drugs for p53 functional restoration in tumors harboring p53 mutations. To overcome this, we have screened for small molecules capable of restoring wild-type p53 pathway signaling rather than direct physical restoration of its function. We identified a small molecule, CB002 analog #4 capable of restoring the p53 pathway in HCT116, SW480 and DLD-1 colorectal cancer cell lines as indicated by the increased expression of p53-target genes NOXA, p21 and DR5, and apoptotic markers upon treatment. We found that analog #4 enhances ethidium homodimer staining of dead cells and decreases the number of positive Ki67 staining cells in colorectal cancer patient organoids. Sub-G1 analysis demonstrated that analog #4 does not induce apoptosis in normal human fibroblasts and preliminary in vivo studies indicate that it can be safely administered to mice. We are investigating the in vivo efficacy of analog #4 in addition to its mechanism of action through micro-array experiments. Our data supports the concept that small molecules can restore the p53-pathway as a therapeutic strategy that can be translated into a clinical setting.
Citation Format: Liz J. Hernandez Borrero, Avital Lev, Lanlan Zhou, David T. Dicker, Wafik S. El-Deiry. Newly identified p53-pathway restoring small molecule, CB002 analog #4 induces apoptosis and appears non-toxic in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3878.
Abstract 3886: Impact of nanosuspension of CZ48, a lactone stabilized camptothecin, on the biliary excretion and enterohepatic recycling of its active moiety, camptothecin
Authors: Chow Diana S-L , Kim Yu Jin , Dong Dong , Li Xiaohui 
Published: August 2019

Abstract
The biliary excretions of CZ48, a lactone-stabilized camptothecin (CPT), and CPT were evaluated in bile duct-cannulated SD rats after a single oral administration of CZ48 in two different types of formulations, co-solvent solution (CoS, control, in the mixture of DMSO, PEG 400, and EtOH (2:2:1, v/v/v) at 10 mg/ml) and nanosuspension (NS with stabilizers of TW 80 and F-108, sustained release of CZ48). Enterohepatic recycling was further characterized by collecting bile intermittently or continuously to modulate the recycling system in the rats. The results demonstrated that CZ48 and CPT were secreted into the bile as their parent forms with the dominant secretion of CPT as compared to CZ48. The AUCs0-12h of CPT in bile were 213.45 ± 232.09 and 250.40 ± 134.83 ng/ml*h/[mg/kg] in CoS and NS groups, respectively, which were 18.39 and 34.16 times higher than those of CZ48 (11.61 ± 7.99 ng/ml*h/[mg/kg] in the CoS group and 7.33 ± 2.22 ng/ml*h/[mg/kg] in the NS group). On the contrary, the AUCs0-12h of CZ48 in plasma were 6.10 and 6.80 times higher than those of CPT in CoS and NS groups, respectively. There was no significant impact of NS on the plasma AUCs0-12h and biliary excretions of CZ48 and CPT. Their concentrations in plasma and biliary excretions were sustained for 8 or 12 h post oral dose. Moreover, a pharmacokinetic co-model for CZ48 and CPT in plasma and bile was developed to characterize the biliary secretion and saturable process of enterohepatic recycling of CZ48 and CPT in rats.
Citation Format: Diana S-L Chow, Yu Jin Kim, Dong Dong, Xiaohui Li. Impact of nanosuspension of CZ48, a lactone stabilized camptothecin, on the biliary excretion and enterohepatic recycling of its active moiety, camptothecin [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3886.
Abstract 3892: Population pharmacokinetics of siltuximab: An analysis across tumor types
Authors: Nikanjam Mina , Yang Jin , Capparelli Edmund V. 
Published: August 2019

Abstract
Introduction: Siltuximab is an IL-6 inhibiting monoclonal antibody which has been studied in solid tumors and hematologic malignancies, but no comprehensive pharmacokinetic (PK) analysis has been conducted to determine the impact of disease on siltuximab disposition.
Methods: Siltuximab pharmacokinetic data from 7 Phase I and II clinical trials included healthy subjects, Castleman’s disease, ovarian cancer, non-Hodgkin’s lymphoma, multiple myeloma, smoldering multiple myeloma, chronic lymphocytic leukemia, renal cell carcinoma, and solid tumors with KRAS mutations. Siltuximab was most commonly dosed at 11 or 15 mg/kg (range 1 - 20 mg/kg) with 70% of patients receiving multiple doses. Plasma samples were obtained 0.33 h - 27 weeks after dosing with siltuximab concentrations determined using a validated ELISA assay. The PK analysis was performed using nonlinear mixed effects modeling (NONMEM 7.3) and included data from 465 subjects (7,761 samples).
Results: Siltuximab concentration data was best fit with a two-compartment model. Healthy volunteer status (HV), Castleman’s disease (CD), albumin (ALB), and ALT were independent predictors of clearance (CL), while ALB, HV, serum creatinine (SCR), weight (WT), and smoldering multiple myeloma predicted volume of distribution (Vdss). There was no impact of dose level on CL or Vdss. In the final PK model CL was described as:
CL (mL/hr) = 8.93 x (ALB/4.1)-0.843 x (ALT/17)-0.0964 x 1.24 (if HV) x 0.765 (if CV);
between subject variability was 41.0%. The final model was used to simulate a dose of 11 mg/kg for 1000 subjects with the median (IQR) exposure (AUC) and CL as follows:
CL (mL/hr)AUC (mcg*day/mL)Half-lifeβ (days)Healthy volunteers6.61 (4.99 – 8.63)4,855.8 (3,717.4 - 6,426.3)24.5 (19.2 – 33. 6)Castleman’s Disease11.11 (8.48 - 14.36)2,884.3 (2,233.7 - 3,782.5)19.1 (14.6 - 25.0)Other tumor types9.13 (6.93 - 11.52)3,514.5 (2,786.2 - 4,627.0)22.2 (17.5 - 30.5)
Conclusions: This combined population PK analysis demonstrates that clearance can differ with disease type consistent with previously published variations in IL-6 activity. These population differences along with significant between subject variability suggest that clinical and disease factors influence siltuximab disposition and may need to be considered in dosing requirements.
Citation Format: Mina Nikanjam, Jin Yang, Edmund V. Capparelli. Population pharmacokinetics of siltuximab: An analysis across tumor types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3892.
Abstract 3894: Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranialTPM3-NTRK1mutant tumor model
Authors: Cruz Cecile C. de la , Hunsaker Thomas , Vazvaei Faye , Draganov Dragomir , Yu Li , Merchant Mark 
Published: August 2019

Abstract
Entrectinib is a selective and brain penetrant inhibitor with potency against TRKA, TRKB, TRKC, ROS1 and ALK currently in clinical development for the treatment of tumors harboring NTRK or ROS1 gene fusions. In multiple non-clinical models harboring NTRK or ROS1 gene fusions, entrectinib demonstrates potent tumor growth inhibition leading to tumor regressions. Entrectinib achieves exposure in the brain across multiple species with brain-to-plasma concentration ratios of 0.4 in mice, 0.6-1.5 in rats, and 1.4-2.2 in dogs after multiple oral administration. Previously Cook, et al. demonstrated that entrectinib demonstrates anti-tumor efficacy in a BCAN-NTRK1 glioma model, however only testing higher doses. Here we sought to better understand the effective exposures of entrectinib required for pathway inhibition and anti-tumor efficacy through dose-ranging efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) studies using the TPM3-NTRK1 KM12-Luciferase (KM12-Luc) tumor model inoculated subcutaneously or intracranially. In the subcutaneous setting, entrectinib treatment results in significant dose-dependent inhibition of TRKA pathway signaling for up to 12 hours and anti-tumor activity with doses of 5 mg/kg (dosed orally (PO), every day (QD)) and above resulting in strong pathway suppression and tumor regressions. PK analysis demonstrated that an exposure of AUC24h of ≥20 µM.hr was associated with potent TRKA pathway inhibition and tumor growth inhibition. In the intracranial setting, entrectinib similarly demonstrated a dose-dependent effect on inhibition of tumor bioluminescence and enhanced animal survival. Pathway inhibition was observed at all doses of entrectinib with significant activity observed at doses of 5 mg/kg, PO, QD and above. In contrast to tumors inoculated subcutaneously, entrectinib doses of 15 mg/kg, PO, twice daily (BID) or 30 mg/kg, PO, QD were required to strongly inhibit anti-tumor efficacy with the highest dose of 60 mg/kg, PO, BID achieving full suppression of intracranial tumor growth. These data help to establish a model connecting entrectinib drug exposure in circulation and in the brain to pathway suppression and anti-tumor efficacy in an NTRK gene fusion tumor model, which support clinical use of entrectinib in patients with brain NTRK or ROS1 gene fusion tumors.
Citation Format: Cecile C. de la Cruz, Thomas Hunsaker, Faye Vazvaei, Dragomir Draganov, Li Yu, Mark Merchant. Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranialTPM3-NTRK1mutant tumor model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3894.